Oral nitrite restores age-dependent phenotypes in eNOS-null mice

JCI Insight. 2018 Aug 23;3(16):e122156. doi: 10.1172/jci.insight.122156.

Abstract

Alterations in the synthesis and bioavailability of NO are central to the pathogenesis of cardiovascular and metabolic disorders. Although endothelial NO synthase-derived (eNOS-derived) NO affects mitochondrial long-chain fatty acid β-oxidation, the pathophysiological significance of this regulation remains unclear. Accordingly, we determined the contributions of eNOS/NO signaling in the adaptive metabolic responses to fasting and in age-induced metabolic dysfunction. Four-month-old eNOS-/- mice are glucose intolerant and exhibit serum dyslipidemia and decreased capacity to oxidize fatty acids. However, during fasting, eNOS-/- mice redirect acetyl-CoA to ketogenesis to elevate circulating levels of β-hydroxybutyrate similar to wild-type mice. Treatment of 4-month-old eNOS-/- mice with nitrite for 10 days corrected the hypertension and serum hyperlipidemia and normalized the rate of fatty acid oxidation. Fourteen-month-old eNOS-/- mice exhibited metabolic derangements, resulting in reduced utilization of fat to generate energy, lower resting metabolic activity, and diminished physical activity. Seven-month administration of nitrite to eNOS-/- mice reversed the age-dependent metabolic derangements and restored physical activity. While the eNOS/NO signaling is not essential for the metabolic adaptation to fasting, it is critical for regulating systemic metabolic homeostasis in aging. The development of age-dependent metabolic disorder is prevented by low-dose replenishment of bioactive NO.

Keywords: Fatty acid oxidation; Metabolism; Nitric oxide; Therapeutics.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Administration, Oral
  • Aging / drug effects
  • Aging / metabolism*
  • Animals
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Fasting / metabolism
  • Homeostasis / drug effects*
  • Humans
  • Hyperlipidemias / drug therapy
  • Hyperlipidemias / genetics
  • Hyperlipidemias / metabolism
  • Hypertension / drug therapy
  • Hypertension / genetics
  • Hypertension / metabolism
  • Male
  • Mice
  • Mice, Knockout
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type III / deficiency*
  • Nitric Oxide Synthase Type III / genetics
  • Signal Transduction / drug effects
  • Sodium Nitrite / administration & dosage*
  • Time Factors
  • Treatment Outcome

Substances

  • Nitric Oxide
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse
  • Sodium Nitrite